| Big Pharma's Emerging Market Fever: Abbott Aims for the Top of India's Industry The Burrill Report submits: By Marie Daghlian Emerging market M&A headlined the third week of May as Big Pharma continued its push into emerging markets. Abbott Laboratories (ABT) wasted no time after creating its Established Product Division to expand its branded generics market share, especially in emerging markets. The company announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business, one of India’s top branded generics companies, for an upfront payment of $2.1 billion, plus $400 million annually for the next four years. The $3.7 billion deal will make Abbott in the leader in the Indian pharmaceutical market. Complete Story » seekingalpha.com |
Panel Wants to Change How We Eat A federal nutrition panel is charged with coming up with recommendations that will figure in the government's planned update of the iconic food pyramid. online.wsj.com |
BioClinica Partners with Axio Research Corporation and Beardsworth Consulting Group (Business Wire) NEWTOWN, Pa.----BioClinicaâ„¢, Inc., , a global provider of clinical trial management services, today announced it has created strategic partnerships with two privately held clinical research organizations , Axio Research Corporation and Beardsworth Consulting Group, Inc. us.rd.yahoo.com |
New Data Supports Valdoxan - Video New Data Supports Valdoxan’s® Unique Clinical Signature feedproxy.google.com |
PAREXEL International to Present at Oppenheimer Healthcare Conference and Morningstar Annual Stocks Forum [PR Newswire] - PAREXEL International Corporation announced today it will be presenting at the Oppenheimer Healthcare Conference in New York. Â James Winschel, Senior Vice President and Chief Financial Officer will be making a presentation on PAREXEL at 2:45 p.m. E.T. on Wednesday, November 3, 2010. us.rd.yahoo.com |